Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
|---|---|---|---|---|---|
| IT1-C53W3 | Cynomolgus | Cynomolgus Integrin alpha 11 beta 1 (ITGA1&ITGB1) Heterodimer Protein, His Tag&Tag Free |  |
|
|
| IT1-C52W9 | Canine | Canine Integrin alpha 11 beta 1 (ITGA11&ITGB1) Heterodimer Protein, His Tag&Tag Free |  |
|
|
| IT1-M52W5 | Mouse | Mouse Integrin alpha 11 beta 1 (ITGA11&ITGB1) Heterodimer Protein, His Tag&Tag Free |  |
|
|
| IT1-H52W3 | Human | Human Integrin alpha 11 beta 1 (ITGA11&ITGB1) Heterodimer Protein, His Tag&Tag Free |  |
|
Immobilized Native Human Collagen I protein at 10 μg/mL (100 μL/well) can bind Canine ITGA11&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-C52W9) with a linear range of 0.078-5 μg/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | Details | |
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | Details |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | Details |
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | Details |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
